Lv3
202 积分 2021-11-17 加入
Abstract 2932: Datopotamab deruxtecan (Dato-DXd) enhances antitumor response to PD-1/PD-L1 inhibitors in TROP2-expressing tumors in mice
2天前
求助中
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
24天前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
2个月前
已完结
Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts
3个月前
已完结
Expression of Potential Antibody–Drug Conjugate Targets in Cervical Cancer
3个月前
已完结
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
3个月前
已完结
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
5个月前
已完结
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial
6个月前
已完结
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
7个月前
已关闭
Towards multimodal foundation models in molecular cell biology
7个月前
已完结
皖公网安备34019202002308
